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Mesenchymal stem cells (MSCs) hold great promise as therapeutic agents in regenerative medicine and autoimmune diseases,
based on their diﬀerentiation abilities and immunosuppressive properties. However, the therapeutic applications raise a series of
questions about the safety of culture-expanded MSCs for human use. This paper summarized recent ﬁndings about safety issues of
MSCs, in particular their genetic stability in long-term in vitro expansion, their cryopreservation, banking, and the role of serum
in the preparation of MSCs.
1.Introduction
It has been shown that the transplantation of mesenchy-
mal stem cells (MSCs) could be an eﬀective therapy for
many diseases including blood disease, acute respiratory
distress syndrome, spinal cord injury, liver injury, and
critical limb ischemia [1–4]. To date, hundreds of clinical
trials using MSCs have been registered in the database
(http://www.clinicaltrials.gov/) of the US national institutes
of health. Furthermore, a number of nonregistered clinical
studies using MSCs are being performed in many countries.
The general practice includes the isolation of MSCs
from various tissues (including bone marrow, adipose tissue,
placenta umbilical cord, umbilical cord blood, peripheral
blood, and dental pulp) and the cell expansion under in
vitro culture conditions. The complications in the utilization
of MSCs as therapeutic tools in vivo arose due to the
experimental artifacts introduced by inconsistent cell culture
protocols. Actually, most MSCs used for clinical trials are
prepared in research laboratories, lacking suﬃcient preclin-
ical studies and manufacturing quality control. Moreover,
laboratories around the world lack an internationally stan-
dardized practice for in vitro expansion of MSCs, resulting in
heterogeneous populations of cells and inconsistent results,
both in experimental studies and clinical trials.
In addition, although MSCs have been used in both
autologous and allogeneic settings, most clinical applications
of MSCs are in fact personalized therapies in which the
patient receives administration of MSCs provided by dif-
ferent donor and/or diﬀerent preparation. This necessitates
the establishment of standardized manufacture guidelines
for the isolation, expansion, preservation, and delivery of
MSCs that display minimal variability in their production
and assumes large-scale produced MSCs as “cell medicine”
for safety evaluation and clinical applications.
2. Expansionand GeneticStabilityof MSCs
Primary MSCs are rare in human tissues. The frequency of
MSCs is approximately 1/106 nucleated cells in adult bone
marrow and 1/104 nucleated cells in umbilical cord [5].
T h en u m b e ro fM S C sh a sb e e nn o t e dt od e c r e a s ew i t ha g e .
When grouped by decade, a signiﬁcant decrease in MSCs per
nucleated bone marrow cell could be observed, with 10-fold
decrease from birth to teens and another 10-fold decrease
from teens to elderly [6].
Despitelimitednumber,MSCscanbeexpandedtoahigh
levelinlong-termculturesystem,whichpermitsalarge-scale
production of MSCs for clinical application. Usually, the
adult bone marrow MSCs (BMMSCs) can grow identically2 Stem Cells International
in culture for 6–10 passages, whereas placenta umbilical cord
MSCs can undergo 30 to 40 passages. It is known that pro-
longed culture of human embryonic stem cells (ESCs) can
lead to adaptation and acquisition of chromosomal abnor-
malities [7–12]. The induced pluripotent stem cells (iPSCs)
undergo deletions of tumor-suppressor genes during the
process of reprogramming, while duplications of oncogenic
genes aroused in culture [13]. It remains unclear whether the
“culture-adapted” MSCs undergo adaptive transformation
during long-term passaging in vitro.
Previous data obtained from high-resolution analysis
show that the in vitro expanded human BMMSCs are
devoid of DNA copy number aberrations [14, 15]. However,
senescence-associated modiﬁcation at speciﬁc CpG sites has
been observed in MSC during culture expansion. The key
evidence for transformation based on DNA ﬁngerprinting
has not been presented in the studies in which the authors
claimed that MSCs underwent malignant transformation in
cultivation [16–25]. More data are therefore needed to eval-
uate the genomic stability of MSCs during prolonged culture
in vitro. The highresolution of genetic analysis including
balanced and unbalanced genetic change is an important
method to determine the possibility of transformation of
MSCs. If CNV or SNP change is detected after long-term
cultivation, it refers not only to the occurrence of mutation
but also to the mutation providing a survival (senescence
or apoptosis resistance) or growth advantage more or less.
Even if there is no diﬀerence between early- and late-passage
MSCs in genome, it does not imply the absence of genomic
alteration during long-term cultivation. The mutated MSCs
without survival or growth advantage will be diluted in
the process of cultivation and become undetectable after
long-term cultivation. By contrast, the mutated MSCs with
growth advantage or senescence resistance are of more risk
for clinical application.
3. Tumor Formation
Stem cells posses some features of cancer cells including long
lifespan, relative apoptosis resistance, and ability to replicate
for extended periods of time. In addition, similar growth
regulators and control mechanisms are involved in both
cancer and stem cell maintenance. Therefore, stem cells may
undergo malignant transformation which is often seen as
a key obstacle to the safe use of stem-cell-based medicinal
products.
Some previous studies have described spontaneous
transformationofMSCsinvitro.However,almostallofthem
have not provided solid evaluation of the same origin of
normal MSCs and their transformed counterparts. Actually,
most of the spontaneous malignant transformed MSCs are
cross-contained by HT1080, HEla, or other tumor cell lines
[16, 17, 20, 21, 23–25] .T h e r ei sn oe n o u g he v i d e n c ef o r
tumorigenicity of MSCs expanded in vitro.
To address the safety issues, we conducted several
GLP-compliant in vivo toxicity studies using NOD mice,
NOD/SCID mice, guinea pigs, rabbits, and monkey models.
UC-MSCs from master MSCs bank (passage 2, P2) were
thawed and cultured for additional ﬁve passages (P7)
and eleven passages (P13). At the end of P7 or P13, an
approximate number of 6 × 109 or 5 × 1012 UC-MSCs were,
respectively, harvested, allotted, and cryopreserved until use.
For tumorigenic study, UC-MSCs at adose of 1 ×107/mouse
were subcutaneously transplanted into both NOD mice and
NOD/SCID mice. No tumor formation was observed two
months after cell transplantation in these animals. The eﬀect
oftransplantedUC-MSCsontumorgrowthwasthenstudied
using the Nod mice which were previously injected with
K562 cells to induce leukemic tumors. Two injections (two-
week interval) of diﬀerent doses of UC-MSCs resulted in
a signiﬁcant inhibition of K562 tumor growth in the mice
bearing leukemic tumors. These in vivo results are consistent
with our in vitro results showing a potent inhibitory eﬀect
of UC-MSCs on the proliferation of K562 and HL-60 cells
without inducing apoptosis [26].
In an eﬀort to evaluate the overall toxicology of UC-
MSCs, we have performed an in vivo study in cynomolgus
monkeys receiving repeated administrations of UC-MSC.
The administration of UC-MSC was done by intravenous
injection once every two weeks for six weeks, with a dose
of 2 × 106 or 1 × 107 cells/kg body weight. All ani-
mals survived until scheduled euthanasia. No signiﬁcant
MSCs-related changes were found in body weights, clinical
signs, hematological/biochemical values, organ weights, or
histopathological ﬁndings. The results of this toxicity study
indicated that the transplantation of UC-MSC did not aﬀect
the general health of cynomolgus monkeys [27].
Moreover, the vast majority of clinical trials conducted
with MSCs in regenerative medicine applications have not
reported major health concerns. Centeno et al. report that
two groups of patients (group 1: n = 50; group 2: n = 290)
between 2006 and 2010 were treated for various orthopedic
conditions with culture-expanded, autologous BMMSCs.
Cells were cultured in monolayer culture ﬂasks using an
autologous platelet lysate technique and reinjected into
peripheral joints or into intervertebral discs with use of
c-arm ﬂuoroscopy. Using both intensive high-ﬁeld MRI
tracking and complications surveillance in 339 patients,
no neoplastic complications were detected at any stem
cell reimplantation site [28]. MSCs-based therapy has also
already been used in other human disease settings, such
as graft-versus-host and cardiac disease, with initial reports
indicating a good safety proﬁle. These ﬁndings indicate the
lack of solid evidence for malignant transformation in vivo
following implantation of MSCs for clinical use. Further
studies will be required to determine if MSCs can help
tumor formation and related mechanisms. Although MSCs
with chromosomal alterations did not show any sign of
malignant transformation either in vitro or in vivo [29],
it remains uncertain that acquired mutations will induce
cellular transformation during the prolonged culture. There
exists the possibility that MSCs gain copy number variation
during prolonged expansion. Thus, it is necessary to conduct
aCGH or SNP array to evaluate the genomic integrity of
MSCs before clinical application.Stem Cells International 3
4. Cryopreservationand Banking of MSCs
To isolate and produce in large scale the MSCs for clinical
use, standardized preparation processes and long-term stor-
age of MSCs isolated from diﬀerent sources are needed for
future clinical applications [30–32].
Since HLA-matched adult organ donors are not always
available, stem cells derived from several birth-associated
perinatal tissues—including cord blood, placenta, and
umbilical cord—can be banked as a safeguard against future
life-threatening conditions. The clinical grade production
and preservation of perinatal MSCs necessitates adhering
to cGMP (current Good Manufacture Practices) to insure
the delivery of a “cell drug” that is not only safe but
also reproducible and eﬃcient. Cryopreservation of cells
permits the transportation of cells between sites, as well
as completion of safety and quality control testing. Taken
together, banking of perinatal MSCs includes the donor
determination and sample collection, primary cell isolation
and microbiological testing, the master stem cell selection,
cell expansion, cryopreservation and banking, and the large-
scale cell expansion and preparation of ﬁnal stem cell
products. Strict standards and management are vital to
make stem cell bank work well. Validated SOPs (Standard
Operation Procedures) with quality assurance programs are
the key factorof a well-designed bank of MSCs. Maintenance
of viability, biological characteristics, and sterility makes the
banked MSCs safety and “ready to use.”
It has been demonstrated that cryopreservation does
not change the biological behavior of MSCs such as dif-
ferentiation, growth, and surface marker [33]. Serum and
dimethyl sulfoxide (DMSO) are used in research laboratory
as cryoprotectant. The major challenge of freezing MSCs is
the toxicity of cryoprotectant in clinical use. The toxicity of
DMSO is overestimated as it could be weakened by diluting
cyropreserved MSCs before clinical use. FBS (fetal bovine
serum), BSA (bovine serum albumin), or HSA (human
serum albumin) should not be an alternative cyroprotectant
forDMSObecauseofariskofcontaminationwithhumanor
animal viruses.
5.Serum-Containingand
Serum-FreeCultivations
In vitro expansion of MSCs is conventionally achieved in
medium containing FBS and is increased by addition of
growth factors. However, for widespread clinical applica-
tions, contact of MSCs with serum must be minimized since
it is a putative source of prion or virus transmission. Serum
is the most uncertain factor in the expansion of clinical
grade MSCs. Considering the batch-to-batch variability and
possibility of viral contamination, some replacement of
FBS such as human AB serum or platelet lysates cannot
be considered as better choice for producing MSCs for
clinical use [34]. Chemical-deﬁned, xeno-free, serum-free
medium (SFM) may conquer all the problems of FBS.
Furthermore, comparing serum-contained medium, some
evidence supported that SFM provided an adjuvant for
maintenance of chromosomal stability in BMMSCs and
adipose-derived MSCs [35]. Another study focus on mouse
embryo ﬁbroblasts showed that predominantly diploid kary-
otype was maintained in serum-free culture even at PD60.
Aneuploid karyotype was induced by the addition of serum
[36]. Probably the uncontrolled mitogenic stimulation in
serum can lead to strong genetic instability. However,
expansion of MSCs in SFM remains an unsolved question.
SFM has its own shortcoming in the preparation of clinical
grade MSCs. The attachment of MSCs in SFM needs the
coating of ﬁbronectin or other substrates which contained
components of human origin and batch-to-batch variability
and cannot be well deﬁned chemically.
In fact, SFM is not as well as that some commercial
companies claimed. Based on our own data, UC-MSCs
proliferate more slowly in SFM than in FBS-contained
media.Sometimes,UC-MSCscannotbeexpandedinSFM.A
number of studies have revealed that MSCs can be expanded
in FBS contained medium without transformation [14]. If
MSCs are expanded in SFM, the similar safety studies are
needed to determine if the serum-free system aﬀects the
genetic stability of MSCs and cause tumor formation.
In summary, the safety remains one of the main concerns
in cell therapy. The production of safe cell products requires
an entire process supervising to make sure the cells maintain
overall phenotype, functional potential, and to ensure the
cultured cells remain untransformed and no microbiological
contaminations. Therefore, MSCs banking and cell products
manufacturing and corresponding quality control system
procedures must be applied for assuring the safety and
eﬃciency of the ﬁnal cell products. Moreover, we cannot
only rely on biologists to produce MSCs which fulﬁls all of
the requirements for clinical application. Cell engineering
technologies are needed in the translation from expansion of
MSCsinlaboratorytolarge-scalemanufactureincellfactory.
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